Bioceres Crop Solutions Corp.

Bioceres Crop Solutions Corp. operates in the agricultural industry, focusing on productivity solutions designed to regenerate agricultural ecosystems and enhance crop resilience to climate change. The company's business model encompasses technology sourcing, product development, production, and market access, leveraging both in-house R&D and strategic partnerships. The industry is characterized by a growing global demand for food, projected to increase by approximately 50% by 2050 ¹, alongside the need for sustainable intensification of agriculture to mitigate climate change and biodiversity loss. This creates a substantial opportunity for innovation in climate-adaptive biotechnology, biological products, and precision agriculture tools. The global biologicals market was estimated at approximately $15 billion in 2024 ² and is the fastest-growing segment in agricultural inputs, with double-digit growth industry-wide compared to low-single-digit growth for conventional products. The global seed market was estimated at $72 billion in 2024 ³ and is projected to reach $99.9 billion by 2030 ⁴, with genetically modified seeds being one of the fastest-growing segments, estimated at approximately $39.9 billion in 2024 ⁵ and projected to reach $92.4 billion by 2033 ⁶.

The company faces intense competition in the crop productivity sector from large companies such as Bayer, BASF, Corteva, Syngenta AG, UPL Limited, and FMC Corporation, as well as bio-specialized businesses like BioSAfe Systems, Certis Biologicals, Gowan, Novozymes, and Valent Biosciences. Bioceres Crop Solutions positions itself with a pioneering high-impact technology platform, including the HB4® drought-tolerant technology for soybean and wheat, and a broad portfolio of biologicals. The company holds or licenses over 750 patents and patent applications ⁷ and over 1,394 trademarks ⁸ globally. Its capital-efficient, risk-mitigated development model involves co-funding projects with partners to reduce financial burden and risk, while maintaining a controlling interest in the developed products or technologies.

The core business model of Bioceres Crop Solutions generates revenue through a multi-channel sales structure comprising direct sales via proprietary channels (Rizobacter, Bioceres Semillas, Pro Farm), B2B commercial agreements, and licensing of commercial technology to third parties. The company's revenue mix includes both product sales and royalty income from licensed technologies. Primary customer segments include global blue-chip companies, industry leaders, large distributors, co-ops, dealers, and individual growers. The company's ecosystem includes over 15 collaborations and joint initiatives globally.

The company's business is divided into three segments: Crop Protection, Seed and Integrated Products, and Crop Nutrition. The Crop Protection segment includes high-tech adjuvants and pest control molecules (biopesticides like biological fungicides, insecticides, and nematicides). For the year ended June 30, 2025, this segment generated $181.9 million in revenue ⁹ with a 38% gross margin ¹⁰. The Seed and Integrated Products segment focuses on seed traits (primarily HB4® drought-tolerant technology for soybean and wheat), germplasm, and seed treatment packs. This segment reported $63.7 million in revenue ¹¹ with a 30% gross margin ¹² for the year ended June 30, 2025. The Crop Nutrition segment offers inoculants, biofertilizers, micro-beaded fertilizers, and crop health products. This segment contributed $89.5 million in revenue ¹³ with a 48% gross margin ¹⁴ for the year ended June 30, 2025.

For the fiscal year ended June 30, 2025, total revenue from contracts with customers and initial recognition and changes in the fair value of biological assets at the point of harvest decreased by $129.7 million ¹⁵, or 28% ¹⁶, to $335.1 million ¹⁷ compared to $464.8 million ¹⁸ in the prior year. Gross profit decreased by $54.9 million ¹⁹, or 29% ²⁰, to $131.7 million ²¹ from $186.6 million ²² in the prior year, with the full-year gross margin holding stable. Operating loss was $2.2 million ²³, compared to an operating profit of $45.9 million ²⁴ in the prior year. Net loss for the year was $58.8 million ²⁵, compared to a profit of $7.3 million ²⁶ in the prior year. Diluted EPS is not explicitly stated. Adjusted EBITDA was $28.3 million ²⁷, a decrease from $81.4 million ²⁸ in the prior year. Cash and cash equivalents amounted to $32.7 million ²⁹ as of June 30, 2025. Total indebtedness was $260.2 million ³⁰, with $222.0 million ³¹ maturing in the fiscal year ending June 30, 2026, and $102.3 million ³² reclassified as a current liability due to a breach of financial covenants.

Year-over-year comparisons for the fiscal year ended June 30, 2025, show a significant decline in revenue across all segments. Crop Protection revenue decreased by $41.6 million ³³, or 19% ³⁴, to $181.9 million ³⁵, primarily due to reduced commercialization of third-party products in Argentina, partially offset by a $5.8 million ³⁶ increase in bioprotection products. Crop Nutrition revenue decreased by $55.3 million ³⁷, or 38% ³⁸, to $89.5 million ³⁹, mainly due to a sharp contraction in micro-beaded fertilizer sales and a $15.7 million ⁴⁰ reduction related to the Syngenta downpayment. Seed and Integrated Products revenue decreased by $32.5 million ⁴¹, or 34% ⁴², to $63.9 million ⁴³, reflecting the transition to a licensing-based model for HB4®. Gross margin for Crop Nutrition declined from 53% to 48% ⁴⁴, while Crop Protection saw an improved gross margin due to a reduction in low-margin third-party products and a more favorable product mix.

During the fiscal year ended June 30, 2025, Bioceres Crop Solutions implemented a major restructuring of its seed business, discontinuing direct commercialization of HB4® wheat and soybean seeds and transitioning to a licensing-based model for the HB4® trait. Key agreements included a strategic agreement with Grupo Don Mario (GDM) in February 2025 for soybean varieties and an agreement with the Colorado Wheat Research Foundation (CWRF) in September 2025 for exclusive rights to manage access to the HB4® trait in wheat within the United States. The company also recorded a gain from the exchange of intangible assets of $7.5 million ⁴⁵ due to a transaction involving non-core soybean traits and intellectual property assets.

The company's near-term growth strategy is focused on several key priorities, including continuing to advance agricultural biotechnology and biological products by consolidating leadership in biologicals and selectively advancing biotechnology assets, with a focus on microbial technologies and seed traits. This integrated approach aims to develop superior yielding products that support both crop performance and sustainable production practices.

Another major growth vector involves optimizing manufacturing capacity. Significant investments have been made to expand and modernize the production footprint, including a new high-tech adjuvant facility plant in Londrina, Brazil, with an annual capacity of approximately 2.6 million gallons ⁴⁶, which increased manufacturing capacity four-fold. In Argentina, biologicals production capacity was expanded by 60% ⁴⁷. The Pro Farm Merger incorporated a 11,400 square-foot manufacturing facility in Bangor, Michigan ⁴⁸, with an annual capacity of up to 0.6 million gallons ⁴⁹ for biopesticides and a formulation plant for insecticides and fungicides with a production capacity of up to 0.8 million gallons ⁵⁰ per year. These investments provide the installed capacity needed to support international expansion.

The company plans to commercialize HB4® traits through licensing partnerships. Following the restructuring of the seed business, royalties from HB4® licenses are expected to represent a growing component of revenues. Strategic partnerships with leading breeders and seed companies are intended to expand the portfolio of HB4® products and increase adoption through third-party commercial channels.

International expansion is a key operational outlook. The company operates through subsidiaries in Argentina, Brazil, the United States, Bolivia, Colombia, France, Paraguay, South Africa, Uruguay, and other markets, supported by a global sales force. Continued international growth is expected to be driven primarily by biologicals, complemented by the expansion of high-value adjuvants and nutrition technologies.

The company intends to pursue strategic collaborations and selective acquisitions that align with its strategic focus, expand its global presence, and provide access to validated later-stage technologies. In evaluating such opportunities, the company intends to remain disciplined and prioritize partnerships and transactions that are capital-efficient and synergistic with its existing portfolio.

The company's ability to generate cash flow over the next twelve months depends on the success of initiatives to optimize working capital and realign cost structure, as well as discussions regarding a new long-term facility or capital raise and refinancing current debt with local Argentine banks. The financial statements for the year ended June 30, 2025, state that substantial doubt exists about the company's ability to continue as a going concern.

The company faces material risks, including challenges in servicing its indebtedness, particularly the recently amended Convertible Notes and Non-Convertible Notes, with $102.3 million ⁵¹ reclassified as a current liability as of June 30, 2025, due to a breach of financial covenants. The aggregate principal amount of Convertible Notes increased to $67,868,227 ⁵² with a 15% annual interest rate ⁵³ and maturity extended to August 31, 2027 ⁵⁴, while Non-Convertible Notes total $29,081,233 ⁵⁵ with a 19% annual interest rate ⁵⁶. The company will need additional capital, and an inability to obtain it on acceptable terms may limit business plan execution. The HB4® seed business is dependent on a licensed technology subject to termination provisions and a transition from direct seed sales to a licensing-based model, which may result in lower or more volatile revenues. Adverse economic or political conditions in Latin America, particularly Argentina, including inflation (CPI increased 117% in August 2024 ⁵⁷), government controls, and currency fluctuations (Argentine Peso depreciated 27.37% against the U.S. dollar in 2024 ⁵⁸), may impact financial results. Global economic conditions, including armed conflicts and tariffs (Argentine exports to the United States are subject to a 10% tariff ⁵⁹, except steel and aluminum at 50% ⁶⁰), could adversely affect the business. Intense competition in crop productivity products, requiring continuous technological development, and changes in laws and regulations, including those affecting GM crops and intellectual property, could increase costs or decrease revenue. The company also faces risks from price increases and shortages of raw materials, commodity price volatility, uninsured product liability claims, and health and environmental risks from handling potentially toxic materials. Intellectual property protection is challenged by potential disclosure of proprietary information, difficulties in global enforcement, and changes in patent law, such as Russia's decree permitting use of certain patents without compensation ⁶¹.

Management's message to shareholders emphasizes a long-term growth strategy based on an open-architecture approach to technology origination, identifying and accessing promising third-party technologies, and forming strategic, capital-efficient partnerships. The near-term strategic priorities include continuing to advance agricultural biotechnology and biological products by consolidating leadership in biologicals and selectively advancing biotechnology assets, with a focus on microbial technologies and seed traits. A second priority is to optimize manufacturing capacity, leveraging significant investments in new facilities such as the high-tech adjuvant plant in Brazil with an annual capacity of approximately 2.6 million gallons ⁶² and a 60% ⁶³ expansion of biologicals production capacity in Argentina. The third strategic priority is to commercialize HB4® traits through licensing partnerships, expecting royalties from HB4® licenses to represent a growing component of revenues following the restructuring of the seed business. Management also highlights strengthening international expansion, particularly for biologicals, adjuvants, and nutrition products, and pursuing selective acquisitions and in-licensing opportunities that are capital-efficient and synergistic with the existing portfolio. The company's financial statements for the year ended June 30, 2025, state that there is substantial doubt about its ability to continue as a going concern.